Measurement of Some Biochemical Parameters in Metabolic Syndrome

Suhair Abdul-Raheem  Ahmed; Israa Fadhil  Ascar

doi:10.30526/38.3.3750

Authors

Suhair Abdul-Raheem Ahmed Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq. https://orcid.org/0009-0000-0557-9814
Israa Fadhil Ascar Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq. https://orcid.org/0000-0002-0793-6659

DOI:

https://doi.org/10.30526/38.3.3750

Keywords:

Lipid profile, Liver enzymes, Metabolic syndrome, Obestatin, Osteopontin

Abstract

Patients with diabetes, high blood pressure (BP), and obesity have metabolic syndrome (MetS). The study aims to evaluate the levels of obestatin and osteopontin (OPN) as markers for detecting MetS and their relationship with other biomarker parameters at Al-Yarmuk Teaching Hospital in Baghdad. A total of 165 patients (125 with MetS and 40 healthy subjects as a control group) whose ages ranged from 20 to 80 years were examined and participated in this study. Body mass index (BMI), BP, fasting serum glucose (FSG), liver enzymes, total protein, and serum lipid profile were evaluated in each patient and control. In addition, obestatin and OPN were used with commercial ELISA kits according to the manufacturer's instructions. The study's results showed significant differences (p < 0.05) in BMI, blood pressure (BP), fasting serum glucose (FSG), liver enzymes, and lipid profile between the MetS and control groups. The levels of obestatin were notably decreased in the MetS group compared to the control group (280.8 pg/mL vs. 1082.1 pg/mL). The level of OPN in patients was significantly higher than in controls (17.96 ng/mL vs. 5.47 ng/mL), respectively. The receiver operating characteristic (ROC) curve tests for obestatin and OPN are 0.981 and 0.999, respectively, which indicate that Obestatin and OPN are considered good diagnostic markers for subjects with MetS. It can be proposed that decreased levels of obestatin and increased levels of OPN in obese individuals may contribute to the onset of MetS and disrupted lipoprotein metabolism.

Author Biographies

Suhair Abdul-Raheem Ahmed , Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq.

Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq.
Israa Fadhil Ascar , Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq.

Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq.

References

1. Stetic L, Belcic I, Sporis G, Stetic L, Starcevic N. Influence of physical activity on the regulation of disease of elderly persons with metabolic syndrome. Int J Environ Res Public Health. 2021;18(1):275. https://doi.org/10.3390/ijerph18010275

2. Shafeeq NK, Hussein TAA, Abass EAA. Metabolic syndrome. Ibn Al-Haitham J Pure Appl Sci. 2021;34(3):26–38. https://doi.org/10.30526/34.3.2675

3. Myers J, Kokkinos P, Nyelin E. Physical activity, cardiorespiratory fitness, and the metabolic syndrome. Nutrients. 2019;11(7):1652. https://doi.org/10.3390/nu11071652

4. Zamil AH, Amin SS. The prevalence of metabolic syndrome among university students in Wasit, Iraq. Saudi Med J. 2022;43(11):1240–1247. https://doi.org/10.15537/smj.2022.43.11.20220558

5. Karakoç Z, Topaloğlu U, Bayram B. Immunohistochemical distributions of leptin, ghrelin and obestatin hormones in bull and ram abomasum. Anat Histol Embryol. 2022;51(3):411–418. https://doi.org/10.1111/ahe.12801

6. Egido EM, Hernández R, Marco J, Silvestre RA. Effect of obestatin on insulin, glucagon and somatostatin secretion in the perfused rat pancreas. Regul Pept. 2009;152(1-3):61–66. https://doi.org/10.1016/j.regpep.2008.08.003

7. Khalil NO, Sheta YS, Khalil UA, Rashad NM, Abd ElFatah AH, Sami MM. A brief insight about obestatin possible relation with diabetes complications. Tob Regul Sci. 2023;10:2937–2942. https://doi.org/10.18001/TRS.9.1.202

8. Tahir NT, ALfatlawi WR, Jedda WAA. Ghrelin and obestatin levels as a novel marker in Iraqi obese children. Baghdad Sci J. 2023;20(5). https://dx.doi.org/10.21123/bsj.2023.7103

9. Mallikarjuna BG, Manjappara UV. Obestatin and rosiglitazone differentially modulate lipid metabolism through peroxisome proliferator-activated receptor-γ (PPARγ) in pre-adipose and mature 3T3-L1 cells. Cell Biochem Biophys. 2021;79(1):73–85. https://doi.org/10.1007/s12013-020-00958-7

10. Szentpeteri A, Lorincz H, Somodi S, Varga VE, Seres I, Paragh G, et al. Human obestatin level and its correlations with metabolic syndrome components in non-diabetic obese patients. Atherosclerosis. 2017;263:e250. https://doi.org/10.1016/j.atherosclerosis.2017.06.811

11. Cowan E, Burch KJ, Green BD, Grieve DJ. Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes. Br J Pharmacol. 2016;173(14):2165–2181. https://doi.org/10.1111/bph.13502

12. Green BD, Grieve DJ. Biochemical properties and biological actions of obestatin and its relevance in type 2 diabetes. Peptides. 2018;100:249–259. https://doi.org/10.1016/j.peptides.2017.12.006

13. Bora RR, Prasad R, Khatib MN. Cardio-protective role of a gut hormone obestatin: A narrative review. Cureus. 2023;15(4):e37972. https://doi.org/10.7759/cureus.37972

14. Lin EYH, Xi W, Aggarwal N, Shinohara ML. Osteopontin (OPN)/SPP1: From its biochemistry to biological functions in the innate immune system and the central nervous system (CNS). Int Immunol. 2023;35(4):171–180. https://doi.org/10.1093/intimm/dxac060

15. Ascar IF. Biochemical study on a group of Iraqi patients with thyroid cancer in relation to osteopontin [dissertation]. Baghdad: University of Baghdad, College of Sciences for Women; 2019.

16. Kitamura K. Osteopontin. In: Takei Y, Ando H, Tsutsui K, editors. Handbook of hormones. Amsterdam: Elsevier; 2021. p. 597–599. https://doi.org/10.1016/B978-0-12-820649-2.00152-2

17. Al-Husaini FK, Hywar FA, Elias NG, Falih IQ. Evaluation of chemerin in diabetic type 2 patients with metabolic syndrome in both genders. Iran J War Public Health. 2022;14(4):409–414. https://doi.org/10.29252/ijwph.14.4.409

18. Parker J. Glucose metabolism, energy production and regulation of cellular and whole-body metabolism. J Australas Coll Nutr Environ Med. 2020;39(1):29–33. https://doi.org/10.3316/informit.154784110868319

19. Kunzova S, Maugeri A, Medina-Inojosa J, Lopez-Jimenez F, Vinciguerra M, Marques-Vidal P. Determinants of metabolic health across body mass index categories in Central Europe: A comparison between Swiss and Czech populations. Front Public Health. 2020;8:108. https://doi.org/10.3389/fpubh.2020.00108

20. Arnlov J, Ingelsson E, Sundström J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation. 2010;121(2):230–6. https://doi.org/10.1161/CIRCULATIONAHA.109.887521

21. Amini M, Zayeri F, Salehi M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: Results from Global Burden of Disease Study 2017. BMC Public Health. 2021;21(401):1–12. https://doi.org/10.1186/s12889-021-10429-0

22. Alowfi A, Binladen S, Irqsous S, Khashoggi A, Khan MA, Calacattawi R. Metabolic syndrome: Prevalence and risk factors among adolescent female intermediate and secondary students in Saudi Arabia. Int J Environ Res Public Health. 2021;18(4):2142. https://doi.org/10.3390/ijerph18042142

23. Natesan V, Kim SJ. Lipid metabolism, disorders and therapeutic drugs–review. Biomol Ther. 2021;29(6):596. https://doi.org/10.4062/biomolther.2021.122

24. Vasse J, Lassartesse A, Marmontel O, Charrière S, Bouveyron C, Marrié N. Assessment of three equations to calculate plasma LDL cholesterol concentration in fasting and non-fasting hypertriglyceridemic patients. Clin Chem Lab Med. 2023;62(2):270–279. https://doi.org/10.1515/cclm-2023-0360

25. Tachebele B, Abebe M, Addis Z, Mesfin N. Metabolic syndrome among hypertensive patients at University of Gondar Hospital, North West Ethiopia: A cross sectional study. BMC Cardiovasc Disord. 2014;14(177):1–9. http://www.biomedcentral.com/1471-2261/14/177

26. Okafor CI. The metabolic syndrome in Africa: Current trends. Indian J Endocrinol Metab. 2012;16(1):56–66. https://doi.org/10.4103/2230-8210.91191

27. Zhang L, Ma X, Jiang Z, Zhang K, Zhang M, Li Y, et al. Liver enzymes and metabolic syndrome: A large-scale case-control study. Oncotarget. 2015;6(29):26782. https://doi.org/10.18632/oncotarget.5792

28. Paredes S, Fonseca L, Ribeiro L, Ramos H, Oliveira JC, Palma I. Novel and traditional lipid profiles in metabolic syndrome reveal a high atherogenicity. Sci Rep. 2019;9:11792. https://doi.org/10.1038/s41598-019-48120-5

29. Kosmas CE, Rodriguez Polanco S, Bousvarou MD, Papakonstantinou EJ, Peña Genao E, Guzman E, et al. The triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) ratio as a risk marker for metabolic syndrome and cardiovascular disease. Diagnostics. 2023;13(5):929. https://doi.org/10.3390/diagnostics13050929

30. Szentpeteri A, Lorincz H, Somodi S, Varga VE, Paragh G, Seres I, et al. Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients. Lipids Health Dis. 2018;17(1):1–8. https://doi.org/10.1186/s12944-018-0691-y

31. Sarac F, Basoglu O, Gunduz C, Bayrak H, Avci CB, Akcicek F. Association of osteopontin and tumor necrosis factor-α levels with insulin resistance in obese patients with obstructive sleep apnea syndrome. J Endocrinol Invest. 2011;34(7):528–533. https://doi.org/10.3275/7287

32. Bartosińska J, Przepiórka-Kosińska J, Sarecka-Hujar B, Raczkiewicz D, Kowal M, Chyl-Surdacka K, et al. Osteopontin serum concentration and metabolic syndrome in male psoriatic patients. J Clin Med. 2021;10(4):755. https://doi.org/10.3390/jcm10040755

33. Ahmad R, Al-Mass A, Al-Ghawas D, Shareif N, Zghoul N, Melhem M, et al. Interaction of osteopontin with IL-18 in obese individuals: Implications for insulin resistance. PLoS One. 2013;8(5):e63944. https://doi.org/10.1371/journal.pone.0063944

34. Nahm FS. Receiver operating characteristic curve: Overview and practical use for clinicians. Korean J Anesthesiol. 2022;75(1):25–36. https://doi.org/10.4097/kja.21209